Decoding TL1A Blockade: Emerging Therapeutic Strategies for Bridging Critical Gaps in IBD Management

Clinical Conversation

link will be live on 6/15
Post-Test & Claim Credit (link live on 6/15)

This activity is jointly provided by Global Education Group (Global) and Bonum CE in collaboration with MondayNightIBD.

This activity is supported by an educational grant from Sanofi.

Program Overview

The introduction of novel anti-interleukin-23 antibodies began with ustekinumab in 2016. The field has evolved with the recent approval of multiple drugs also targeting the p19 subunit. This specific targeting of the p19 subunit of IL-23 attempts to reduce inflammation and improve outcomes. This Tweetorial activity will focus on the role of these novel agents in the treatment of inflammatory bowel disease (IBD).

Faculty

Aline Charabaty, MD, FACG, AGAF (program chair)
Professor of Medicine
Director of the Inflammatory Bowel Disease Program
Division of Gastroenterology and Hepatology
University of Maryland Medical Center
Baltimore, MD

Vipul Jairath, MBChB, DPhil (guest faculty)
Professor of Medicine
Departments of Medicine, Epidemiology and Biostatistics
John and Susan McDonald Endowed Chair in IBD Clinical Research Director
Advanced IBD Fellowship Program
Associate Chair (Research)
Department of Medicine
Schulich School of Medicine & Dentistry
Western University
London, Ontario

Target Audience

The target audience for this program is IBD specialists, gastroenterologists, gastroenterology fellows and trainees, nurse practitioners and physician’s assistants who care for patients with IBD. Additionally, nurses, specialty pharmacists and other healthcare practitioners involved or interested in the care of patients with IBD.

Learning Objectives

After completing this activity series, learners should be better able to:
1. Identify the current unmet clinical needs in IBD management, including remission rates, fibrotic complications, and patient treatment priorities.
2. Explain the pathophysiological mechanisms of the TL1A/DR3 pathway in IBD-associated inflammation and fibrosis.

Disclosure of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

  • Aline Charabaty, MD, FACG, AGAF
    Consultant & Advisor: AbbVie, Eli Lilly, Janssen, Pfizer, Sanofi

    Vipul Jairath, MBChB, DPhil
    Consulting Fees: Abbvie, Alimentiv, Amgen, Anaptys Bio, Asahi Kasei, Asieris, Astra Zeneca, Attovia, Blackbird Labs, BMS, Boehringer Ingleheim, Biomebank, Cabaletta, Caldera, Calluna, Catalytic Health, Celltrion, Ensho, Enthera, Enveda, Exeliome Biosciences, Ferring, Fresenius Kabi, Gilead, Granite Bio, GSK, Janssen, Lilly, Merck, Mobius, Mountainfield, MRM Health, Nxera, Orbimed, Organon, OSE Immunotherapeutics, Palisade Bio, Pendopharm, Pfizer, PharmaNest, Pioneering Medicine, PIPr Therapeutics, Roche/Genentech, Sanofi, SCOPE, Shattuck Labs, Sorriso, Spyre, Synedgen, Takeda, Teva, Tillotts, Throne Scientific, Tr1X Inc., Union Therapeutics, Ventus, Ventyx, Vividion, Xencor, Zealand Pharma

  • The planners and managers at Global Education Group have no relevant financial relationships to disclose.

    Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Disclosure of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

 

  • Aline Charabaty, MD, FACG, AGAF
    Consultant & Advisor: AbbVie, Eli Lilly, Janssen, Pfizer, Sanofi

    Vipul Jairath, MBChB, DPhil
    Consulting Fees: Abbvie, Alimentiv, Amgen, Anaptys Bio, Asahi Kasei, Asieris, Astra Zeneca, Attovia, Blackbird Labs, BMS, Boehringer Ingleheim, Biomebank, Cabaletta, Caldera, Calluna, Catalytic Health, Celltrion, Ensho, Enthera, Enveda, Exeliome Biosciences, Ferring, Fresenius Kabi, Gilead, Granite Bio, GSK, Janssen, Lilly, Merck, Mobius, Mountainfield, MRM Health, Nxera, Orbimed, Organon, OSE Immunotherapeutics, Palisade Bio, Pendopharm, Pfizer, PharmaNest, Pioneering Medicine, PIPr Therapeutics, Roche/Genentech, Sanofi, SCOPE, Shattuck Labs, Sorriso, Spyre, Synedgen, Takeda, Teva, Tillotts, Throne Scientific, Tr1X Inc., Union Therapeutics, Ventus, Ventyx, Vividion, Xencor, Zealand Pharma

Certification

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Bonum Continuing Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Release date: June 15, 2026
Expiration date: June 15, 2027
Estimated time to complete activity: 60 minutes